3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Neoplasms
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Meningeal Carcinomatosis
1
Interventions
pembrolizumab
61
Carboplatin
44
Pemetrexed
31
Paclitaxel
31
Docetaxel
31
Cisplatin
27
Gemcitabine
24
Nivolumab
23
Erlotinib Hydrochloride
21
Bevacizumab
18
Ipilimumab
11
osimertinib
10
Drug Therapy
10
atezolizumab
9
Radiosurgery
9
Cyclophosphamide
9
Cetuximab
9
Blood Specimen Collection
9
durvalumab
8
cemiplimab
8
Radiotherapy
8
budigalimab
7
Fluorouracil
7
Dexamethasone
7
trametinib
6
fludarabine
6
dostarlimab
6
avelumab
6
Taxes
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
AZD3759
×
Thoracic
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled